Orchid Pharma Ltd

Stage 3 · Topping · week 5

As of 20 Nov 2026, Orchid Pharma is in Stage 3, the topping phase, now in week 5 (since 21 Oct 2026). It closed at ₹960, 13.3% below its 52-week high and above its 200-day average, which is rising. In Health Care, 34.7% of stocks are in Stage 2.

Orchid Pharma Limited, a pharmaceutical company, engages in the development, manufacture, and marketing of active pharmaceutical ingredients, bulk actives, finished dosage formulations, and nutraceuticals in India. More about the company

₹960.4
Close, 20 Nov 2026
+1.24% on the day
₹4,871 Cr · Small cap
Market DowntrendHealth Care 34.7% in Stage 2-11.4 pts / 20dPharmaceuticals 42.4%-13.9 pts

Pro read

Pro

Our read

Topping: the uptrend is tiring

Setup score

—

RS rank

Edge

—

ORCHPHARMA's uptrend is tiring: 5 weeks into a top. A topping stock either breaks back out or rolls over into a decline, and the next few weeks usually settle which.

Its relative strength is 80 of 99, a leader among NSE stocks over the past year. Pharmaceuticals ranks 7 of 106 industries by the strength of its stocks, among the leaders.

Is ORCHPHARMA early, or has it already run? Pro answers that for every NSE stock, after every close.

Loading price chart…
Stage Cycle Timeline2023-08-24 → 2026-11-20
S2 24w
S2 17w
S4 22w
S4 13w
S2 18w
2023-08-242026-11-20
S1S2S3S4Setup score (0–10, dashed line at 5)
S2 6w → S3 8w → S2 24w → S3 5w → S2 17w → S3 5w → S2 10w → S3 4w → S4 22w → S1 10w → S4 4w → S1 2w → S2 7w → S3 3w → S4 13w → S1 4w → S2 18w → S3 4w current
Total tracked: 167 weeks across 18 stage runs.

ORCHPHARMA among Pharmaceuticals44th of 118 by relative strength

All 118 →
Stocks in Pharmaceuticals ranked by relative strength, with stage and one-month change
#StockStageRS1M
1BLISSGVSStage 2 · wk 4999+4.6%
2KPLStage 2 · wk 4499+20.5%
3FREDUNStage 2 · wk 3398+24.0%
4VENUSREMStage 3 · wk 1098−1.5%
5RUBICONStage 3 · wk 498+18.7%
6SAKARStage 2 · wk 5598+13.1%
7BAFNAPHStage 2 · wk 2398+1.9%
8INDSWFTLABStage 2 · wk 2398−7.4%
…44ORCHPHARMAStage 3 · wk 580+8.3%
vs 52W High
-13.3%
₹482.5 lo₹1,107.2 hi
13.3% below 52W high, weakening from peak
The stock is rolling over from its 52-week high. In Stage 3 distribution, new long positions carry high risk.
Stage Maturity
Week 5
1w13w26w
Week 5, early distribution
How long this stock has been in Stage 3 distribution. Longer tops often precede deeper Stage 4 declines.
vs 200 DMA
16.5%
200 DMA: ₹824.6 · rising
The stock still holds above its 200-day average, but the trend has flattened. A close below the line would add to the Stage 4 risk.
Rel Volume
0.58x
vs 50-day avg
Volume was well below average. Quiet sessions say little in a topping stock. Volume on the down days matters more.
Trend Health
↓
Short-term trend rolling over
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
+8.3%
3M
-1.9%
6M
+34.3%
YTD
+26.5%
1Y
+20.3%
Sector
Health Care
↓ Peaking
Stage 2%
34.7%
20d Δ
-11.4pp
1M return
+11.5%
3M return
+3.8%
Sector Stage-2 % · last 20 days
Sector has 58 Stage 2 leaders. See Health Care Stage 2 →
Industry
Pharmaceuticals
↓ Peaking
Stage 2%
42.4%
20d Δ
-13.9pp
1M return
+8.3%
3M return
+2.1%
Industry Stage-2 % · last 20 days
Industry has 48 Stage 2 leaders. See Pharmaceuticals Stage 2 →

Mutual fund holdings

Held by 14 mutual funds in portfolios to October 2026: 10 active funds and 4 index funds and ETFs.

In October, among active funds: 1 increased.

1 increased or opened0 reduced or exited
Largest active holders, by weight in the fund
All 14 funds and what each did in October

Mutual funds holding ORCHPHARMA: the ten largest and the month’s moves →

Fund details on DiscoverMF

Scan Membership
Not in any scan now.
Last appeared 7 Oct 2026
Last appeared 25 Aug 2026
Last appeared 19 Jun 2026
3 appearances in the last 60 days.
Recent Stage Timeline
2026-11-20S3
Wk 5 · Vol 0.58x
2026-11-19S3
Wk 5 · Vol 0.97x
2026-11-18S3
Wk 4 · Vol 2.07x
2026-11-17S3
Wk 4 · Vol 1.17x
2026-11-16S3
Wk 4 · Vol 8.75x
2026-11-13S3
Wk 4 · Vol 0.96x
2026-11-12S3
Wk 4 · Vol 0.21x
2026-11-11S3
Wk 3 · Vol 0.61x
2026-11-09S3
Wk 3 · Vol 0.41x
2026-11-06S3
Wk 3 · Vol 0.32x
2026-11-05S3
Wk 3 · Vol 0.58x
2026-11-04S3
Wk 3 · Vol 0.41x
Moving averages & range
50 DMA
₹946.8
200 DMA
₹824.6
52W High
₹1,107.2
52W Low
₹482.5
5D Low
₹924.3
Resistance levels (recent highs)
20d High
₹960.4
60d High
₹1,107.2
120d High
₹1,107.2
250d High
₹1,107.2
Next resistance
+15.3%
to 60d High
P/E (TTM)
549.3
Forward 21.1
Earnings Growth (YoY)
-81.6%
Revenue +75.9%
Dividend Yield
0.00%
P/B 3.5

Orchid Pharma: quick answers

What stage is Orchid Pharma in?

As of 20 Nov 2026, Orchid Pharma (ORCHPHARMA) is in Stage 3, the topping phase. It entered Stage 3 on 21 Oct 2026 and is in week 5. What the four stages mean

Is Orchid Pharma in an uptrend?

Its uptrend has stalled. Orchid Pharma is in Stage 3, the topping phase that follows an advance. It trades 16.5% above its 200-day average, which is rising.

How far is Orchid Pharma from its 52-week high?

Orchid Pharma closed at ₹960 on 20 Nov 2026, 13.3% below its 52-week high of ₹1,107. Its 52-week low is ₹482.

How has Orchid Pharma performed over the past year?

As of 20 Nov 2026, Orchid Pharma is up 20.3% over the past year and up 26.5% so far in 2026.

Which sector and industry is Orchid Pharma in?

Orchid Pharma is in the Pharmaceuticals industry, part of the Health Care sector. 61 stocks in Health Care are in Stage 2, 34.7% of the sector. See the Stage 2 stocks in Pharmaceuticals

About this companyHealth Care· Pharmaceuticals

Orchid Pharma Limited, a pharmaceutical company, engages in the development, manufacture, and marketing of active pharmaceutical ingredients, bulk actives, finished dosage formulations, and nutraceuticals in India. Its active pharmaceutical ingredients product portfolio includes oral cephalosporins, injectable cephalosporins; human and veterinary products; and antibiotics, including betalactam, macrolide, fluoroquinolone, and imidazole. The company also exports its products to approximately 40 countries internationally. The company was formerly known as Orchid Chemicals & Pharmaceuticals Limited and changed its name to Orchid Pharma Limited in October 2015. Orchid Pharma Limited was incorporated in 1992 and is headquartered in Chennai, India. Orchid Pharma Limited operates as a subsidiary of Dhanuka Laboratories Limited.

Visit company website →

All analytics based on EOD data. Data as of 2026-11-20. Past data patterns are not indicative of future results. This page is a data analytics tool only.